Stronger STD Warning For Vaginal Antifungals Suggested By Advisory Cmte.
This article was originally published in The Tan Sheet
Executive Summary
Prominent, more specific cautionary statements in OTC vaginal anitfungal labeling to help ensure consumers do not misdiagnose more serious conditions, such as sexually transmitted diseases, for a yeast infection, were supported by FDA advisory committee members at a Sept. 11 meeting in Bethesda, Md.